Clicky

2seventy bio, Inc.(TSVT)

Description: 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc. operates independently of bluebird bio, Inc. as of November 4, 2021.


Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell

Home Page: www.2seventybio.com

TSVT Technical Analysis

60 Binney Street
Cambridge, MA 02142
United States
Phone: 339 499 9300


Officers

Name Title
Mr. Nick Leschly Pres, CEO & Director
Mr. William D. Baird III Chief Financial Officer
Ms. Nicola H. Heffron Chief Operating Officer
Ms. Susan Abu-Absi Ph.D. Chief Technology & Manufacturing Officer
Dr. Philip D. Gregory D. Phil., DPHIL Chief Scientific Officer
Ms. Teresa L. Jurgensen J.D. VP, Gen. Counsel & Corp. Sec.
Ms. Kathleen A. Wilkinson Head of People & Culture
Mr. Kevin Chin M.D., M.S. Head of Clinical Devel.
Mr. Steven Shamah Ph.D. Head of Oncology Research
Ms. Jenn Snyder Head of Corp. Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.4431
Price-to-Sales TTM: 8.24
IPO Date: 2021-11-03
Fiscal Year End: December
Full Time Employees: 437
Back to stocks